{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 38,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial structure (Screening, Part A, Part B).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/16",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Phase 3 design – NeflgArd trial flow showing screening, randomization, 9 months treatment, 3 months follow-up, and Part B long-term follow-up.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d286179-e6f1-45d4-add7-624982257b71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.35,
        "y": 0.38
      },
      "kind": "legend",
      "text": "4Q 2020: Expected topline readout of 200 patients; 2022: Expected readout on 360 patients",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69fc881c-f620-40df-82ba-bde6c680ae36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Phase 3 study design evaluates the same primary endpoint as Phase 2b trial; Fixed 16 mg Nefecon once daily oral dose; Reduction of proteinuria: Accelerated approval in U.S. and conditional approval in E.U. based on Part A data; Full approval on 2-year eGFR based endpoint – 360 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0e462f9-dc42-45b9-b668-d0129113689b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Ongoing pivotal Phase 3 clinical trial (NeflgArd) designed to confirm Phase 2b results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10fe0c99-b5f8-4447-b2ae-7c3982fc5558",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "9544c838-18b6-42cb-ae0f-3734a87bd3cc",
      "evidence": "The slide maps out the clinical trial stages chronologically.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}